Question-and-Answer Session
Operator
Thank you. (Operator instructions) Your first question comes from the line of Eric Schmidt representing Cowen & Company. Please proceed.
Eric Schmidt – Cowen & Company
Hi, good morning. Thanks for taking my call. Don, in terms of the operating cash used in the quarter, are you owed some payments from HHS or shipments is delivered they haven't received cash for is that made operating cash went down?
Don Elsey
The operating cash went down on a number of reasons, but yes. Our AR has increased over what it was before we're now at an AR level of $22 million.
Eric Schmidt – Cowen & Company
And in terms of the subtle change to revenue guidance highest toward the lower end of the previous range, is the only change there that you're now not necessarily show about four year dating or have you taken out any initial DoD revenues I assume that's also –
Don Elsey
Clearly, there are a number of factors that play in the overall revenue projections. I would say the primary influence is the four year dating in, I would want to stress it's not that we're changing our view on the achievability of four year dating, it's strictly a timing expectation that instead of being that in this year, it might go out into the first quarter of next year.
Eric Schmidt – Cowen & Company
And I take from Fuad's comments that you're basically planning to sell out your capacity this year 7 million to 8 million doses BioThrax to HHS, if you got some orders from DoD, could you fill them or would they not be applicable to the guidance for 2008 either?
Fuad El-Hibri
Currently – let me just answer that question, if I may. We are confident that we will be delivering everything we produce this year. So, whether it is under HHS or DoD, this is something the government will work out between them. So, point is that we believe that we will be able to sell all that we can produce this year.
Eric Schmidt – Cowen & Company Thanks a lot.
Operator
Next question comes from the line of Cory Kasimov representing JP Morgan. Please proceed.
Cory Kasimov – JP Morgan
Hi, good morning, guys. First question is on rPA. Can you expand a little bit on the stability improvement that has been made there over the issues that VaxGen hadn't, the reasons for your confidence that these issues have been adequately answered?
- To read the full transcript on Seeking Alpha, click here »
